Becca Resnik, RN

home / authors / becca-resnik-rn

Articles

Woman with supplements in her hand.

Fighting the Flu With Supplements: The Pharmacist’s Patient Counseling Guide

Becca Resnik, RN
July 19th 2024

Confusing product labeling and conflicting data can create challenges for patients.

Read More

Phase 3 Trials Demonstrate Efficacy of Immune Checkpoint Inhibitors for Lung Cancer in Older Adults

Phase 3 Trials Demonstrate Efficacy of Immune Checkpoint Inhibitors for Lung Cancer in Older Adults

Becca Resnik, RN
January 26th 2024

Older patients’ underrepresentation in clinical trials leaves a gap in data regarding appropriate treatment.

Read More

Image credit: Caphira Lescante | stock.adobe.com

Study: Substantial Deficiencies in Capture of Cognitive Safety in Drug Trials

Becca Resnik, RN
December 4th 2023

Despite nearly one-third of reversible dementia cases being drug induced, cognitive safety is a neglected aspect of clinical trials.

Read More

Latest Updated Articles

AI patient pharmacist provider interactions ASHP summer
Published: June 11th 2024 | Updated: July 27th 2024
Balancing Trust and Technology: The Role of AI in Patient-Pharmacist Interactions
AI pharmacy futures AI disparities skin
Published: June 11th 2024 | Updated: July 27th 2024
Addressing Disparities in AI-Driven Diagnostics: Ethical and Practical Implications
Vice President Kamala Harris -- Image credit: Erin Schaff/Pool/AFP | GETTY | People.com
Published: July 23rd 2024 | Updated: July 27th 2024
VP Kamala Harris’s Policies and Stances on Health Care, Reproductive Rights Take Center Stage
3d illustration of Abstract medical background with Diseased liver - Image credit: Rasi | stock.adobe.com
Published: October 18th 2023 | Updated: July 27th 2024
Pharmacists Can Optimize Treatment for Patients with NASH, Decreasing Economic Burden
Small vial of influenza vaccine.
Published: July 23rd 2024 | Updated: July 27th 2024
Trivalent Influenza Vaccines Are Readied for Fall
Eye Care Pharmacy | Image Credit: I Viewfinder - stock.adobe.com
Published: July 15th 2024 | Updated: July 27th 2024
Biosimilar Ranibizumab Could be More Cost-Effective Than Aflibercept for nAMD